Hepatitis b virus hbsag surface protein antigen
Heplisav B, PreHevbri (hepatitis b virus hbsag surface protein antigen) is an unknown pharmaceutical. Hepatitis b virus hbsag surface protein antigen was first approved as Heplisav b on 2021-02-18. It has been approved in Europe to treat hepatitis b.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1881 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis b | D006509 | — | — | 168 | 270 | 248 | 327 | 521 | 1470 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | 160 | 264 | 235 | 318 | 482 | 1396 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 126 | 219 | 173 | 275 | 383 | 1124 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 114 | 183 | 95 | 197 | 262 | 817 |
| Chronic hepatitis | D006521 | — | K73.9 | 66 | 114 | 61 | 117 | 139 | 474 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 4 | 11 | 7 | 18 | 67 | 103 |
| Infections | D007239 | EFO_0000544 | — | 15 | 16 | 15 | 18 | 38 | 97 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 14 | 18 | 5 | 7 | 56 | 91 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 14 | 18 | 5 | 7 | 54 | 90 |
| Fibrosis | D005355 | — | — | 5 | 10 | 5 | 19 | 54 | 89 |
Show 100 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Meningitis | D008581 | HP_0001287 | G03 | — | 1 | 7 | — | 3 | 11 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | 1 | 2 | — | 7 | 10 |
| Bacterial infections | D001424 | — | A49 | — | 2 | 7 | — | — | 9 |
| Measles | D008457 | — | B05 | — | 2 | 2 | — | 4 | 8 |
| B-cell lymphoma | D016393 | — | — | — | 3 | 2 | — | 2 | 7 |
| Meningococcal meningitis | D008585 | EFO_1001040 | A39.0 | — | — | 6 | — | 1 | 7 |
| Disease progression | D018450 | — | — | — | — | 1 | — | 5 | 6 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | 1 | 1 | — | 4 | 6 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | — | 2 | 1 | — | 3 | 5 |
| Leukemia | D007938 | — | C95 | — | 1 | 1 | — | 3 | 5 |
Show 44 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute liver failure | D017114 | HP_0004448 | — | — | 1 | — | — | 4 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | 2 | 4 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | 1 | 3 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | 2 | 3 |
| Schistosomiasis | D012552 | EFO_1001475 | B65 | 2 | 1 | — | — | 1 | 3 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | 1 | 2 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 1 | — | — | 1 | 2 |
| Colonic neoplasms | D003110 | — | C18 | — | 1 | — | — | 1 | 2 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 1 | — | — | — | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | 1 | 1 | — | — | 1 | 2 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Medication adherence | D055118 | EFO_0006344 | — | 1 | — | — | — | 3 | 4 |
| Hookworm infections | D006725 | EFO_0007314 | B76 | 4 | — | — | — | — | 4 |
| Ancylostomiasis | D000724 | EFO_0007145 | B76.0 | 4 | — | — | — | — | 4 |
| Vaccine-preventable diseases | D000079263 | — | — | 1 | — | — | — | 3 | 4 |
| Hiv seropositivity | D006679 | — | — | 1 | — | — | — | 2 | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | 2 | 3 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | — | — | — | 1 | 2 |
| Alcoholic liver cirrhosis | D008104 | EFO_1000802 | K70.3 | 1 | — | — | — | — | 1 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | 1 | — | — | — | — | 1 |
| Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | 1 | — | — | — | — | 1 |
Show 12 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sexually transmitted diseases | D012749 | — | A50-A64 | — | — | — | — | 8 | 8 |
| Contraception | D003267 | — | — | — | — | — | — | 5 | 5 |
| Intestinal diseases | D007410 | HP_0002242 | K63.9 | — | — | — | — | 4 | 4 |
| Syphilis | D013587 | EFO_0007504 | A53.9 | — | — | — | — | 4 | 4 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | — | — | — | 3 | 3 |
| Thrombocytopenic purpura | D011696 | — | — | — | — | — | — | 3 | 3 |
| Purpura | D011693 | HP_0000979 | D69.2 | — | — | — | — | 3 | 3 |
| Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | — | — | — | — | 3 | 3 |
| Pregnancy rate | D018873 | — | — | — | — | — | — | 3 | 3 |
| Atrophy | D001284 | — | — | — | — | — | — | 3 | 3 |
Show 194 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Hepatitis b virus hbsag surface protein antigen |
| INN | — |
| Description | Heplisav B, PreHevbri (hepatitis b virus hbsag surface protein antigen) is an unknown pharmaceutical. Hepatitis b virus hbsag surface protein antigen was first approved as Heplisav b on 2021-02-18. It has been approved in Europe to treat hepatitis b. |
| Classification | Unknown |
| Drug class | antivirals |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297973 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Heplisav b – Dynavax Technologies
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 58,085 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
396 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use